Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study
Corresponding Author
K Nezvalová-Henriksen
Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo,
Kateřina Nezvalová-Henriksen, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, PO Box 1065 Blindern, Oslo, N-0316, Norway. Tel. + 47-2284-4761, fax + 47-2285-4402, e-mail [email protected]Search for more papers by this authorO Spigset
Department of Clinical Pharmacology, St Olav's University Hospital and
Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, and
Search for more papers by this authorH Nordeng
Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo,
The Division for Mental Health, National Institute of Health, Oslo, Norway
Search for more papers by this authorCorresponding Author
K Nezvalová-Henriksen
Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo,
Kateřina Nezvalová-Henriksen, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, PO Box 1065 Blindern, Oslo, N-0316, Norway. Tel. + 47-2284-4761, fax + 47-2285-4402, e-mail [email protected]Search for more papers by this authorO Spigset
Department of Clinical Pharmacology, St Olav's University Hospital and
Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, and
Search for more papers by this authorH Nordeng
Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo,
The Division for Mental Health, National Institute of Health, Oslo, Norway
Search for more papers by this authorAbstract
Nezvalová-Henriksen K, Spigset O & Nordeng H. Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study. Cephalalgia 2009. London. ISSN 0333-1024
Little is known about factors associated with migraine pharmacotherapy during pregnancy. Of 60 435 pregnant women in a population-based cohort, 3480 (5.8%) reported having migraine during the first 5 months of pregnancy. Of these, 2525 (72.6%) reported using migraine pharmacotherapy, mostly non-narcotic analgesics (54.1%) and triptans (25.4%). After adjustment for sociodemographic factors and comorbidities in logistic regression analysis, high pregestational body mass index [odds ratio (OR) 1.3, 95% confidence interval (CI) 1.2, 1.4], sleep < 5 h (OR 1.6, 95% CI 1.3, 1.9), being on sick-leave (OR 1.3, 95% CI 1.2, 1.5) and acute back/shoulder/neck pain (OR 0.6, 95% CI 0.6, 0.7) were associated with migraine pharmacotherapy during pregnancy. Many women need drug treatment for migraine during pregnancy, and the choice of pharmacotherapy during this period may be influenced by maternal sociodemographic factors and comorbidities.
References
- 1 Sances G, Granella F, Nappi RE, Fignon A, Ghiotto N, Polatti F et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003; 23: 197–205.
- 2 Melhado EM, Maciel JA Jr, Guerreiro CAM. Headache during gestation: evaluation of 1101 women. Can J Neurol Sci 2007; 34: 187–92.
- 3 Ertresvåg JM, Zwart J-A, Helde G, Johnsen H-J, Bovim G. Headache and transient focal neurological symptoms during pregnancy, a prospective cohort. Acta Neurol Scand 2005; 111: 233–7.
- 4 Maggioni F, Alessi C, Maggino T, Zanchin G. Headache during pregnancy. Cephalalgia 1997; 17: 765–9.
- 5 Marcus DA, Scharff L, Turk D. Longitudinal prospective study of headache during pregnancy and postpartum. Headache 1999; 39: 625–32.
- 6 Granella F, Sances G, Pucci E, Nappi RE, Chiotto N, Nappi G. Migraine with aura and reproductive life events: a case control study. Cephalalgia 2000; 20: 701–7.
- 7 Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA, National Birth Defects Prevention Study. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol 2005; 193: 771–7.
- 8 Nordeng H, Eskild A, Nesheim BI, Aursnes I, Jacobsen G. Drug use during early pregnancy. Eur J Clin Pharmacol 2001; 57: 259–63.
- 9 Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R. Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey. Eur J Epidemiol 2005; 20: 243–9.
- 10 Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA 1992; 267: 64–9.
- 11 Källén B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001; 41: 351–6.
- 12 Norwegian Institute of Public Health. The Norwegian mother and child cohort study. Oslo, Norway: Norwegian Institute of. Public Health 2008. [WWW document]. URL http://www.fhi.no/eway/?pid=238
- 13 WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2008. [WWW document]. URL http://www.whocc.no/atcddd/ (Accessed 3 April 2008).
- 14 Soldin PO, Dahlin J, O'Mara DM. Triptans in pregnancy. Ther Drug Monit 2008; 30: 5–9.
- 15 Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005; 45: 3–31.
- 16 Evans EW, Lorber KC. Use of 5-HT1 agonists in pregnancy. Ann Pharmacother 2008; 42: 543–9.
- 17 Allais G, Castagnoli Gabellari I, Airola G, Schiapparelli P, Terzi MG, Mana O et al. Is migraine a risk factor in pregnancy? Neurol Sci 2007; 28: 184–7.
- 18 Rukmini M, Bushnell CD. Headache and pregnancy. Neurologist 2008; 14: 108–19.
- 19 Silberstein SD, Dodick D, Freitag F, Pearlman SH, Hahn SR, Scher AI et al. Pharmacological approaches to managing migraine and associated co-morbidities—clinical considerations for monotherapy versus polytherapy. Headache 2007; 47: 585–99.
- 20 Schwedt TJ. Serotonin and migraine: the latest developments. Cephalalgia 2007; 27: 1301–7.
- 21 Magnus P, Irgens LM, Haug K, Nystad W, Skjærven R, Stoltenberg C. The MoBa Study Group. Cohort profile: the Norwegian mother and child cohort study (MoBa). Int J Epidemiol 2006; 35: 1146–50.
- 22 Henry A, Crowther C. Patterns of drug use during and prior to pregnancy: the MAP study. Aust NZ J Obstet Gynaecol 2000; 40: 165–72.
- 23 Briggs G, Freeman RK, Yaffe SJ, eds. Ibuprofen. In: Drugs in pregnancy and lactation, 7th edn. Philadelphia, PA: Lippincott Williams & Wilkins 2005: 800–3.
- 24 Schaefer C, Peters P, Miller RK, eds. Migraine medications. In: Drugs during pregnancy and lactation, 2nd edn. London: Elsevier 2007: 42–3.
- 25 Schaefer C, Peters P, Miller RK, eds. ACE inhibitors. In: Drugs during pregnancy and lactation, 2nd edn. London: Elsevier 2007: 203–7.
- 26 Rybaczyk LA, Bashaw MJ, Pathak DR, Moody SM, Gilders RM, Holzschu DL. An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology. BMC Womens Health 2005; 5: 12.
- 27 Calhoun AH, Ford S. Behavioral sleep modification may revert transformed migraine to episodic migraine. Headache 2007; 47: 1178–83.
- 28 Marcus DA. The migraine-sleep link. Headache Pain 2006; 17: 75–8.
- 29 Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007; 27: 394–402.
- 30 Dodick DW, Eross EJ, Parish JM. Clinical, anatomical and physiologic relationship between sleep and headache. Headache 2003; 43: 282–92.
- 31 Toglia JU. Melatonin: a significant contributor to the pathogenesis of migraine. Med Hypotheses 2001; 57: 432–4.
- 32 Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache 2006; 46: 1334–43.
- 33 Jensen R, Stovner LJ. Epidemiology and co morbidity of headache. Lancet Neurol 2008; 7: 354–61.
- 34 Sclar DA, Robison LM, Skaer TL. Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome. Headache 2008; 48: 126–9.
- 35 Wacogne C, Lacoste JP, Guillibert E, Hugues FC, Le Jeune C. Stress, anxiety, depression and migraine. Cephalalgia 2003; 23: 451–5.
- 36 Aamodt AH, Stovner LJ, Langhammer A, Hagen K, Zwart J-A. Is headache related to asthma, hay fever, and chronic bronchitis? The Head-HUNT study. Headache 2007; 47: 204–12.
- 37 Gudmundson LS, Thorgeirsson G, Sigfusson N, Sigvaldason H, Johannsson M. Migraine patients have lower systolic but higher diastolic blood pressure compared with controls in a population-based study of 21 537 subjects. The Reykjavik Study. Cephalalgia 2005; 26: 436–44.
- 38 Bigal M, Lipton B. The prognosis of migraine. Curr Opin Neurol 2008; 21: 301–8.
- 39 James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005; 106: 509–16; 48.
- 40 Adeney KL, Williams MA. Migraine headaches and preeclampsia: an epidemiologic review. Headache 2006; 46: 794–803.
